Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602873 | 0.97 | DAGLB (0.40) | DAGLBCNR2ABHD6DAGLAGRM5 | |
| SCHEMBL3615900 | 0.84 | CNR2 (0.42) | CNR2ABHD6DAGLARAB9ANPC1 | |
| SCHEMBL3605764 | 0.83 | RAB9A (0.39) | CNR2ABHD6DAGLARAB9ANPC1 | |
| SCHEMBL3606003 | 0.81 | CNR2 (0.40) | CNR2ABHD6DAGLAGRM5GRM1 | |
| SCHEMBL3607859 | 0.80 | CYP2D6 (0.38) | CNR2ABHD6DAGLARAB9ANPC1 | |
| SCHEMBL15653975 | 0.76 | DAGLB (0.40) | DAGLBABHD6DAGLARAB9ANPC1 | |
| SCHEMBL3699146 | 0.76 | DAGLB (0.40) | DAGLBABHD6DAGLARAB9ANPC1 | |
| SCHEMBL3602342 | 0.74 | GPR119 (0.39) | KMT2A | |
| SCHEMBL2546757 | 0.72 | POLB (0.41) | DAGLBRAB9ANPC1DPP4 | |
| SCHEMBL2788731 | 0.72 | POLB (0.41) | DAGLBRAB9ANPC1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | DAGLB 829/4885CNR2 204/4885ABHD6 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.